Urovant Sciences is advancing urologic patient care by delivering and developing innovative therapies.
Urovant Sciences is a biopharmaceutical company advancing urologic patient care through development of innovative therapies and exceptional licensing opportunities.
Our goal is to be the leading specialty company, recognized and trusted by patients and providers for our commitment to urology and their well-being. Urologic conditions can have a major impact on daily life, with those affected often suffering in silence as their conditions are overlooked, misunderstood or not adequately treated.
More than 30 million people in the U.S. live with the bothersome symptoms of overactive bladder (OAB). The FDA has approved Gemtesa® (vibegron) for the treatment of overactive bladder in adult patients.
Urovant Sciences® Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints at 2022 American Urological Association Meeting